(Q36338329)

13 August 2017

1 reference

title

Biomarkers of potential prognostic significance in diffuse large B-cell lymphoma (English)

1 reference

13 August 2017

0 references

Grace Wu

1

1 reference

13 August 2017

Armand Keating

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

13 August 2017

1 reference

13 August 2017

volume

106

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

247-257

1 reference

BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Diffuse large B-cell non-Hodgkin lymphomas: the clinical relevance of histological subclassification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Diffuse large B-cell lymphoma: is morphologic subdivision useful in clinical management?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Variability in immunophenotype in diffuse large B-cell lymphoma and its clinical relevance.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Genomic approaches to hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

bcl-2 rearrangements in de novo diffuse large cell lymphoma. Association with distinctive clinical features

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Clinicopathologic significance and prognostic value of chromosomal imbalances in diffuse large B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Chromosomal imbalances in diffuse large B-cell lymphoma detected by comparative genomic hybridization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

An introduction to the molecular mechanisms of apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

NF-kappaB at the crossroads of life and death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Cell cycle deregulation in B-cell lymphomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma--a Nordic Lymphoma Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Molecular heterogeneity of diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin–cyclin B link

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Proteasome inhibition as a novel therapeutic target in human cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: Clinical relevance in 71 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Immunoglobulin (Ig)/BCL6 versus non-Ig/BCL6 gene fusion in diffuse large B-cell lymphoma corresponds to a high- versus low-level expression of BCL6 mRNA

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Mol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Pathogenetic and clinical implications of Bcl-6 and Bcl-2 gene configuration in nodal diffuse large B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21586

7 January 2021

Identifiers

DOI

10.1002/CNCR.21586

1 reference

13 August 2017

1 reference